Anebulo Pharmaceuticals, Inc. (ANEB)

Market Cap	56.39M
Revenue (ttm)	n/a
Net Income (ttm)	-11.60M
Shares Out	25.63M
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,046
Open	2.28
Previous Close	2.20
Day's Range	2.15 - 2.30
52-Week Range	1.62 - 4.05
Beta	-1.15
Analysts	Strong Buy
Price Target	6.67 (+210.23%)
Earnings Date	Nov 14, 2023

About ANEB

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 7, 2021
• Employees: 2
• Stock Exchange: NASDAQ
• Ticker Symbol: ANEB

Analyst Forecast

According to 3 analysts, the average rating for ANEB stock is "Strong Buy." The 12-month stock price forecast is $6.67, which is an increase of 210.23% from the latest price.

Price Target

$6.67

(210.23% upside)

Analyst Consensus: Strong Buy